APRETUDE Reimbursement Milestones in Scotland and Canada
On February 10, 2025, CAB for PrEP (Apretude) was accepted for restricted use in Scotland for HIV prevention in adults and adolescents, for whom oral PrEP is not appropriate to meet their HIV prevention needs. CAB for PrEP (Apretude) also reached a new milestone for reimbursement in Canada.
Key Details:
- The Scottish Medicines Consortium (SMC) has accepted CAB for PrEP (Apretude) restricted use for high risk individuals (weighing at least 35kg) eligible for PrEP but “for whom oral PrEP is not appropriate to meet their HIV prevention needs”.
- The detailed advice noted that SMC clinical experts view CAB for PrEP as addressing an unmet need for high-risk individuals unable to use oral PrEP due to medical, demographic, or social factors.
- The advice also excludes adherent oral PrEP users from switching to CAB for PrEP.
- This advice applies only if the current NHS Scotland Patient Access Scheme (PAS) agreement remains in place, ensuring the agreed cost-effectiveness, either through the approved PAS arrangement or a list price that is equivalent or lower.
- The approval also confirms that ViiV and SMC reached a pricing agreement, with SMC’s decision factoring in a confidential discount offered on the list price.
- The National AIDS Trust also announced the Apretude approval in Scotland, urging NICE to “move forward with its decision on CAB for PrEP in England and Wales” after its draft guidance delayed reimbursement.
- For further information please reach out to the UK Market Access & Reimbursement Team: Matthew Hawthorne and Breda Patterson or the Global Value & Access team Sat Jandu and Lei Zhu
Apretude has also reached another milestone for reimbursement in Canada. ViiV Healthcare announced it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for Apretude, and a letter of intent has been concluded. Following this milestone, ViiV Healthcare plans to work closely with provincial and territorial governments, as well as other stakeholders, to expedite public reimbursement and availability of the treatment.